INVESTIGATION OF CONDITIONS OF ZIPRASIDONE ISOLATION FROM OBJECTS OF BIOLOGICAL ORIGIN
DOI:
https://doi.org/10.11603/2312-0967.2017.2.7906Keywords:
ziprasidone, isolation, uorescence, liver.Abstract
Introduction. Ziprasidone has been reported to be an effective antipsychotic drug for both positive and negative symptoms of schizophrenia. An overdose or combining it with drugs that cause prolongation of the QT interval, the cardiotoxic effect of the drug is observed. Cardiovascular disorders that occur in this case often cause death.
The aim of the work. So, the aim of the work the was develop the optimal conditions for the isolation and determination of ziprasidone in biological material for the express diagnosis of poisoning.
Materials and Methods. Isolation of ziprasidone from objects of biological origin was carried out with a mixture of acetonitrile – 70 % perchloric acid (1:1) followed by liquid extraction of the preparation with chloroform (pH 11). To clean the extracts from biological samples, Strata-X 30 mg (Phenomenex) solid-phase extraction cartridges were used. Ziprasidone in ethanol solutions and extracts from biological material were identi ed and quanti ed spectro uorimetricaly. The uorescence intensity was measured on a Hitachi MPF4 spectrophotometer (Japan) in quartz single-centrifuge cuvettes at 25 °C.
Results and Discussion. Ef ciency of ziprasidone isolation from model liver samples with oxalic acid acidi ed water is 34–36.1 %. The best results were obtained by infusing a biological material with a mixture of acetonitrile – 70 % perchloric acid (1:1). It allows isolating 71.3 – 74.1 % of this preparation. The limit of ziprasidone quanti cation in liver is 0.15 μg/g; and the relative error is ± 1.39 %.
It was found that the uorescence spectrum of ziprasidone in 96 % ethanol is characterised by the excitation maximum at a wavelength λex = 320 nm and the emission maximum λem at 400 nm. In range of ziprasidone concentrations from 200 to 800 ng/ml the calibration curve is described by dependence Y=0.128ґХ–5.60078 (r = 0.9996), and in the concentration range from 0.8 to 40.0 μg/ml the quantitative content of the preparation is determined by equation: Y=2.55478ґХ+6.63262 (r = 0.9995).
Conclusions. The conditions of ziprasidone identi cation and quantitative determination in extracts from biological material by uorescence spectroscopy have been developed. The developed method of the drug isolation can be recommended for forensic medical examinations introduction for ziprasidone poisoning investigation.
References
Asif M. Antipsychotic agents: pharmacological activities of compounds containing arylpiperazines. International Journal of Current Research in Applied Chemistry & Chemi-cal Engineering. 2016;2.1:1-30.
Alipour A, Cruz R, Lott R. Torsade de pointes after ziprasidone overdose with coingestants. J Clin Psychopharmacol. 2010;30(1):76-7. Available from: http://dx.doi. org/10.1097/jcp.0b013e3181c914d3.
Hasnain M, Vieweg W. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS drugs, 2014;28(10):887-920. Available from: http://dx.doi.org/10.1007/s40263-014-0196-9.
Leonard CE, Freeman CP, Newcomb CW, Bilker WB, Kimmel SE, Strom BL, et al. Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five states. J Clin Exp Cardiolog, 2013;10.6: 1-9. Available from: http://dx.doi.org/10.4172/2155-9880. s10-006.
Levine M, Ruha A. Overdose of atypical antipsychotics. CNS Drugs. 2012;26(7):601-11. Available from: http://dx.doi.org/10.2165/11631640-000000000-00000.
Strom B, Eng S, Faich G, Reynolds R, D’Agostino R, Ruskin J et al. Comparative mortality associated with Ziprasidone and Olanzapine in real-world use among 18.154 patients with schizophrenia: the Ziprasidone observational study of cardiac outcomes (ZODIAC). Am J Psychiatry. 2011;168(2):193-201. Available from: http://dx.doi. org/10.1176/appi .ajp.2010.08040484
Timour Q, Frassati D, Descotes J, Chevalier P, Christe G, Chahine M. Sudden death of cardiac origin and psychotropic drugs. Front Pharmacol. 2012;3. Available from: http:// dx.doi.org/10.3389/fphar.2012.00076.
Garda M, Ortuno J, Cuartero M, Abuherba M. Use of a new ziprasidone-selective electrode in mixed solvents and its application in the analysis of pharmaceuticals and biological fluids. Sensors. 2011;11(12):8813-25. Available from: http://dx.doi.org/10.3390/s110908813.
Lei Y, Zhang W, Li H, Yan M, Zhu R. Determination of Ziprasidone by UPLC-MS-MS and its application to a pharmacokinetic study of Chinese schizophrenics. Chromatographia. 2010;72(9-10):975-9. Available from: http:// dx.doi.org/10.1365/s10337-010-1725-4.
Marghade S, Musmade P, Moorkoth S. High-performance liquid chromatographic assay for Ziprasidone in plasma samples: application to pharmacokinetic studies in rats. J Chromatogr Sci. 2012;50(10):902-8. Available from: http://dx.doi.org/10.1093/chromsci/bms088.
Mercolini L, Protti M, Fulgenzi G, Mandrioli R, Ghedini N, Conca A et al. A fast and feasible microextraction by packed sorbent (MEPS) procedure for HPLC analysis of the atypical antipsychotic ziprasidone in human plasma. J Pharm Biomed Anal. 2014;88:467-71. Available from: http://dx.doi.org/10.1016/j.jpba.2013.09.019.
Zhang G, Terry A, Bartlett M. Determination of the lipophilic antipsychotic drug ziprasidone in rat plasma and brain tissue using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2008;22(7):770-8. Available from: http://dx.doi.org/10.1002/bmc.999.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
